Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-24 pm EST			5-day change	1st Jan Change
785.41 ^USD	+2.45%		+8.22%	+1.74%

Jan. 24	DBS Bank Adjusts Price Target on Eli Lilly to $900 From $1,115, Maintains Buy Rating	MT
Jan. 24	Novo Nordisk rises on positive results for amycretin - 22% weight loss (update)	FW

Sector Update: Health Care

December 04, 2024 at 03:25 pm EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Eli Lilly and Company

DBS Bank Adjusts Price Target on Eli Lilly to $900 From $1,115, Maintains Buy Rating	Jan. 24	MT
Novo Nordisk rises on positive results for amycretin - 22% weight loss (update)	Jan. 24	FW
Jefferies Adjusts Price Target on Eli Lilly to $1,020 From $996	Jan. 22	MT
Robeco Global Consumer Trends down 0.37% in December - up in Novo Nordisk and Eli Lilly	Jan. 22	FW
Health Care Up on GLP-1 Alzheimer's Data -- Health Care Roundup	Jan. 21	DJ
Kyverna Therapeutics Names Naji Gehchan as Chief Medical, Development Officer	Jan. 21	MT
Chinese Regulator Issues Drug Registration Certificate for Shandong Xinhua Pharmaceutical's Diabetes Tablets	Jan. 21	MT
S&P 500 Logs 2.9% Weekly Gain on Easing Inflationary Pressures, Strong Bank Earnings	Jan. 17	MT
What Wegovy's inclusion in Medicare price negotiation means for patients, company	Jan. 17	RE
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
LVMH back ahead of Novo Nordisk on the stock market	Jan. 17
Guggenheim Adjusts Price Target on Eli Lilly to $973 From $995, Maintains Buy Rating	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Outgoing FDA chief flags online weight loss drug dangers	Jan. 16	RE
Berenberg Bank Adjusts Eli Lilly Price Target to $970 From $1,050, Maintains Buy Rating	Jan. 16	MT
TD Cowen Adjusts Price Target on Eli Lilly to $900 From $1,050, Maintains Buy Rating	Jan. 16	MT
Eli Lilly's Omvoh Receives US Approval for Crohn's Disease	Jan. 16	MT
Eli Lilly: FDA approves Omvoh for Crohn's disease	Jan. 16	CF
Correction to Eli Lilly Receives Approval for Crohn's Treatment Article	Jan. 15	DJ
Eli Lilly Receives FDA Approval for Crohn's Disease Treatment	Jan. 15	DJ
Eli Lilly Gets FDA Approval for Omvoh to Treat Crohn's Disease	Jan. 15	MT
FDA Approves Lilly's Omvoh (Mirikizumab-Mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease	Jan. 15	CI
Global markets live: Boeing, Pfizer, Nvidia, Goldman Sachs, Shell...	Jan. 15
Wall Street rallies on inflation and earnings bonanza	Jan. 15

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Employees

43,000

Sector

Pharmaceuticals

Calendar

2025-02-06 - Q4 2024 Earnings Release

More about the company